Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.31 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL21492760 | 1.00 | POLB (0.33) | POLBCTSSCTSKKDM4EMAPT | |
| SCHEMBL12155774 | 0.87 | — | — | |
| SCHEMBL805219 | 0.87 | — | — | |
| SCHEMBL432448 | 0.87 | — | — | |
| Rubidium SCHEMBL9635582 | 0.84 | — | — | |
| SCHEMBL8829580 | 0.84 | — | — | |
| SCHEMBL28263469 | 0.84 | — | — | |
| SCHEMBL9343006 | 0.84 | SMN1; SMN2 (0.38) | POLBKDM4EMAPTTHRBALOX15 | |
| Hydrochloric Acid SCHEMBL3290648 | 0.84 | — | — | |
| Trifluoroacetic Acid SCHEMBL15414556 | 0.84 | PADI4 (0.34) | CTSSCTSKDPP8DPP7DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112218865-B | Pteridinone compounds and uses thereof | 沃泰克斯药物股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| EP-4100064-A1 | TARGETED PLASMA PROTEIN DEGRADATION | Novartis AG (CH) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021156792-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2021-08-12 | — | — | WO | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3784669-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-112218865-A | Pteridinone compounds and uses thereof | 沃泰克斯药物股份有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | POLB 300/4885CTSS 4360/4885CTSK 3692/4885 |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | POLB 300/4885CTSS 4360/4885CTSK 3692/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | POLB 300/4885CTSS 4360/4885CTSK 3692/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | POLB 300/4885CTSS 4360/4885CTSK 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.